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The publication of the ORBITA trial (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) generated an immense amount of discussion, debate, and controversy.1 The editorialists posed 
in their title whether the ORBITA trial is the “Last nail in the coffin for PCI [percutane-
ous coronary intervention] in stable angina?”2 The ensuing press coverage has been 
extensive, although mostly 1-sided, and largely following the negative tone set by the 
editorial. The exchange on social media has been at times vitriolic, both pro and con. 
The number of tweets of the article (1716 as of February 25, 2018) now exceeds the 
number of patients enrolled by >7-fold. Thus, ORBITA has disrupted the orbit of PCI.
On a historical note, the first patient to undergo PCI was an ORBITA-like patient 
with successful treatment of an isolated proximal left anterior descending artery le-
sion, rendering the patient symptom-free for >20 years. It took 40 years to conduct 
ORBITA, a well-designed and -executed trial reporting that PCI for stable angina 
was not superior to a sham procedure in terms of exercise time, the trial’s pri-
mary end point. The main strength of the trial was the sham design, a major step 
forward in coronary intervention, building on the use of sham designs in recent 
trials of renal denervation.3 The assessment of the primary end point at 6 weeks, 
precluding information on long-term outcomes, the inclusion of ~25% of patients 
with mild symptoms prerandomization, the large between-group difference in os-
tial and proximal lesions likely because of the small sample size, and the removal of 
patients after randomization, were all significant limitations of the trial (Table). An 
important unintended consequence of ORBITA has been a misunderstanding that 
the results might also apply to unstable angina or myocardial infarction.
Key scientific questions that have emerged are the following: To whom do the 
results potentially apply? What is the way forward? Today, it is estimated that 
patients fitting the criteria of ORBITA constitute ≈10% of patients undergoing 
PCI.4 An essential first step in these types of patients would be to assess the pres-
ence and magnitude of ischemia and whether invasive angiography should be 
performed. Among those patients who do not require angiography initially, an 
algorithm of stepped medical therapy should be instituted in keeping with current 
clinical practice guidelines. In those patients with continued lifestyle-limiting an-
gina or intolerance to further escalation of medical therapy, coronary angiography 
should be pursued. Those patients with indeterminate lesions should undergo an 
invasive assessment (ie, fractional flow reserve or instantaneous wave-free ratio). 
Based on the totality of the findings, percutaneous revascularization (or surgical 
revascularization for complex multivessel disease) can be performed.
This algorithm seems appropriate for the present, but it does not address the 
seismic implications of ORBITA: that PCI might not actually offer incremental ad-
vantages in symptom relief among patients with stable angina. Then what of the 
future? Does ORBITA need to be replicated in a much larger sample size in an inter-
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national study? We would answer yes, at least before 
the trial results should influence practices that are al-
ready compliant with the current guidelines. We predict 
that an adequately powered trial to evaluate whether 
PCI reduces angina compared with sham control in 
single-vessel disease would show significant improve-
ments in angina burden, exercise time, and quality of 
life, in keeping with trends seen in ORBITA. However, 
one could question the need for such a trial, given large 
randomized trials of bare metal stents versus drug-elut-
ing stents (active control trials) that have already shown 
significantly less angina burden in patients randomized 
to drug-eluting stents.
Should patients with more extensive multivessel coro-
nary artery disease be included in a sham-controlled trial 
of PCI? It is difficult for us to envision that the benefits 
of PCI similar to those of coronary artery bypass grafting 
in terms of symptom relief and quality of life observed 
in patients with multivessel and left main disease are a 
placebo effect.5 Furthermore, because coronary artery 
bypass grafting reduces mortality versus PCI in complex 
multivessel disease in patients with diabetes mellitus, this 
also means that coronary artery bypass grafting for stable 
coronary disease reduces mortality versus medical ther-
apy alone—unless one posits that PCI is actually raising 
mortality versus medical therapy, which is not supported 
by randomized data. Thus, it is likely that PCI of patients 
with sufficient ischemic or atherosclerotic disease burden 
would be able to demonstrate a reduction in mortality 
and myocardial infarction in a trial that enrolls a sufficient 
number of high-risk patients and follows them for a long 
enough period of time. Nevertheless, funding and execut-
ing such a trial may be impractical.
Ongoing large trials, such as ISCHEMIA (International 
Study of Comparative Health Effectiveness With Medi-
cal and Invasive Approaches; NCT01471522), may pro-
vide critical data on the role of invasive management 
and specifically PCI in improving major clinical outcomes 
such as myocardial infarction and death compared with 
optimal medical management. If those hard end points 
are reduced—a high bar to clear—then the discussion 
of symptom relief and improvement in exercise capacity 
remains important but becomes less pressing. It is im-
portant to note that the primary end point of ISCHEMIA 
was recently changed because of an insufficient num-
ber of patients enrolled and, as a consequence, too few 
hard events. The redefined end point includes a broader 
array of clinically relevant events (cardiovascular death, 
myocardial infarction, resuscitated cardiac arrest, or 
hospitalization for unstable angina or heart failure) that 
in some respects may substitute for an ORBITA-2, albeit 
without the sham control.
The role of PCI in acute coronary syndromes is firm 
based on large amounts of randomized data. In that 
setting, underutilization, especially in higher-risk pa-
tients and those with comorbidities, is the larger prob-
lem. In stable angina, the role of PCI will evolve as fur-
ther data become available, and it remains a valuable 
adjunct rather than an alternative to medical therapy. 
Additional PCI trials will certainly be performed. As the 
incidence of stable coronary disease increases globally, 
there will be ample patients available to answer the 
pressing questions regarding the appropriate role of PCI 
and hopefully place PCI in its proper orbit.
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Table. Strengths and Limitations of the ORBITA Trial
Strengths Limitations
Appropriate hypothesis Potential for selection bias 
because of patient removal after 
randomization
Appropriate primary end point Baseline difference in exercise time 
between PCI and control exceeds 
treatment effect
Sham control Low symptom burden (CCS classes 
0–1) in ~25% of patients after 
escalation of antianginal therapy
Successful blinding procedures Imbalance of ostial and proximal 
lesions in favor of control (57% 
vs 37%)
Appropriate PCI technique Insufficient power to detect 
a clinically relevant difference 
between groups
Independent funding Study question is limited to a 
minority of patients undergoing PCI 
in contemporary practice
Transparent reporting
 Protocol
  Coronary angiograms of all 
patients
Lack of extended follow-up results 
beyond 6 weeks
CCS indicates Canadian Cardiovascular Society; and PCI, percutaneous 
coronary intervention.
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